Amphastar PharmaceuticalsAMPH
Market Cap: 2.08B
About: Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Employees: 1,761
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
21% more call options, than puts
Call options by funds: $3.17M | Put options by funds: $2.61M
0.22% more ownership
Funds ownership: 69.51% [Q4 2023] → 69.73% (+0.22%) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]
4% less funds holding
Funds holding: 274 [Q4 2023] → 263 (-11) [Q1 2024]
14% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 99
20% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 55
29% less capital invested
Capital invested by funds: $2.06B [Q4 2023] → $1.47B (-$588M) [Q1 2024]
Research analyst outlook
2 Wall Street Analysts provided 1 year price forecasts over the past 6 months
2 analyst ratings
Piper Sandler David Amsellem | 67%upside $71 | Overweight Reiterated | 27 Jun 2024 |
JP Morgan Ekaterina Knyazkova | 41%upside $60 | Overweight Initiated | 5 Mar 2024 |